Knight Therapeutics Inc (TSE:GUD) had its target price boosted by CIBC from C$9.50 to C$9.80 in a research note published on Friday morning, reports.

Separately, Scotiabank restated an outperform rating and issued a C$9.50 price target on shares of Knight Therapeutics in a research report on Monday, July 18th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Knight Therapeutics has a consensus rating of Buy and a consensus price target of C$9.83.

Analyst Recommendations for Knight Therapeutics (TSE:GUD)

Knight Therapeutics (TSE:GUD) opened at 9.78 on Friday. The firm’s 50-day moving average is $9.20 and its 200 day moving average is $8.65. Knight Therapeutics has a 52-week low of $5.89 and a 52-week high of $9.86. The stock has a market capitalization of $1.30 billion and a PE ratio of 68.87.

About Knight Therapeutics

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

Stock Target Prices

Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.